MA28687B1 - Composes organiques - Google Patents
Composes organiquesInfo
- Publication number
- MA28687B1 MA28687B1 MA29571A MA29571A MA28687B1 MA 28687 B1 MA28687 B1 MA 28687B1 MA 29571 A MA29571 A MA 29571A MA 29571 A MA29571 A MA 29571A MA 28687 B1 MA28687 B1 MA 28687B1
- Authority
- MA
- Morocco
- Prior art keywords
- quinolin
- substituted oxy
- organic compounds
- halo
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/04—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D251/06—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne un procédé permettant de préparer des oxy-5-((R)-2-halo-l-hydroxy-éthyl)-(lH)-quinolin-2-ones substitués à la position 8 ou des solvates acceptables de ceux-ci. Le procédé susmentionné consiste à faire réagir un 5-($g(a)-haloacétyl)-8-substitué oxy-( lH)-quinolin-2-one avec un agent réducteur en présence d'un agent chiral et d'une base afin de former un 8-(substitué oxy)-5-((R)-2-halo-l-hydroxy-éthyl)-( lH)-quinolin-2-one; lequel agent chiral étant représenté par la formule (I) ou par la formule (II), dans ces formules. M, L, X, R1, R2 et R3 sont tels que définis dans la description.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0413960.6A GB0413960D0 (en) | 2004-06-22 | 2004-06-22 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28687B1 true MA28687B1 (fr) | 2007-06-01 |
Family
ID=32799952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA29571A MA28687B1 (fr) | 2004-06-22 | 2006-12-28 | Composes organiques |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20090054653A1 (fr) |
| EP (1) | EP1791820B1 (fr) |
| JP (1) | JP5064214B2 (fr) |
| KR (1) | KR101179302B1 (fr) |
| CN (1) | CN1968927B (fr) |
| AR (2) | AR049553A1 (fr) |
| AT (1) | ATE450512T1 (fr) |
| AU (1) | AU2005254698B2 (fr) |
| BR (1) | BRPI0512298A (fr) |
| CA (1) | CA2566388C (fr) |
| CY (1) | CY1109884T1 (fr) |
| DE (1) | DE602005018076D1 (fr) |
| DK (1) | DK1791820T3 (fr) |
| EC (1) | ECSP067100A (fr) |
| ES (1) | ES2337273T3 (fr) |
| GB (1) | GB0413960D0 (fr) |
| HK (1) | HK1105121A1 (fr) |
| HR (1) | HRP20100087T1 (fr) |
| IL (1) | IL179600A (fr) |
| MA (1) | MA28687B1 (fr) |
| MX (1) | MXPA06014695A (fr) |
| MY (1) | MY142051A (fr) |
| NO (1) | NO339079B1 (fr) |
| NZ (1) | NZ551276A (fr) |
| PE (1) | PE20060304A1 (fr) |
| PL (1) | PL1791820T3 (fr) |
| PT (1) | PT1791820E (fr) |
| RU (1) | RU2383534C2 (fr) |
| SI (1) | SI1791820T1 (fr) |
| TN (1) | TNSN06408A1 (fr) |
| TW (1) | TWI347317B (fr) |
| WO (1) | WO2005123684A2 (fr) |
| ZA (1) | ZA200609257B (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2396987T3 (es) | 2006-06-30 | 2013-03-01 | Novartis Ag | Derivados de quinolina y sus composiciones farmacéuticas |
| EP1914227A1 (fr) * | 2006-08-31 | 2008-04-23 | Novartis AG | Forme crystalline polymorphe d'une dérivé de indan-2-ylamino-hydroxyethyl-quinolinone maleate comme agoniste de 2-adrénorécepteur beta |
| US8877930B2 (en) | 2009-11-04 | 2014-11-04 | Massachusetts Institute Of Technology | Continuous flow synthesis of amino alcohols using microreactors |
| US8680303B2 (en) | 2010-03-01 | 2014-03-25 | Massachusetts Institute Of Technology | Epoxidation catalysts |
| MY156795A (en) | 2010-07-14 | 2016-03-31 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| EP2802581A1 (fr) | 2012-01-13 | 2014-11-19 | Novartis AG | 7,8-dihydropyrido[3,4-b]pyrazines utilisées comme agonistes du récepteur ip pour le traitement de l'hypertension artérielle pulmonaire (htap) et des troubles associés |
| TW201335160A (zh) | 2012-01-13 | 2013-09-01 | Novartis Ag | Ｉｐ受體激動劑之雜環化合物 |
| US9115129B2 (en) | 2012-01-13 | 2015-08-25 | Novartis Ag | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
| EP2802583A1 (fr) | 2012-01-13 | 2014-11-19 | Novartis AG | Pipéridines condensées utilisées comme agonistes du récepteur ip pour le traitement de l'hypertension artérielle pulmonaire (htap) et de troubles associés |
| CN104169282B (zh) | 2012-01-13 | 2016-04-20 | 诺华股份有限公司 | Ip受体激动剂的盐 |
| EP2802582A1 (fr) | 2012-01-13 | 2014-11-19 | Novartis AG | Dihydropyrido [2,3-b]pyrazines fusionnées comme agonistes des récepteurs ip pour le traitement de l'hypertension artérielle pulmonaire (hap) et des troubles connexes |
| WO2014008640A1 (fr) * | 2012-07-11 | 2014-01-16 | 上海威智医药科技有限公司 | Intermédiaire d'indacatérol et procédé de synthèse d'indacatérol |
| EP3138837B1 (fr) | 2012-09-21 | 2021-11-24 | Crystal Pharma, S.A.U. | Base libre d'indacatérol sous forme solide |
| WO2014044288A1 (fr) | 2012-09-21 | 2014-03-27 | Crystal Pharma Sa | Procédés de préparation d'indacatérol et de ses sels pharmaceutiquement acceptables |
| EA028509B1 (ru) | 2012-12-19 | 2017-11-30 | Новартис Аг | Ингибиторы аутотаксина, фармацевтические композиции и комбинации, содержащие их, и их применение в лечении заболеваний и состояний, опосредованных аутотаксином |
| JP2016507582A (ja) | 2013-02-13 | 2016-03-10 | ノバルティス アーゲー | Ｉｐ受容体アゴニスト複素環式化合物 |
| CN105209013B (zh) | 2013-03-14 | 2019-04-26 | 诺华股份有限公司 | 喷雾干燥制剂经喷雾混合的脱非晶化 |
| US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| CZ306252B6 (cs) | 2013-03-15 | 2016-10-26 | Zentiva, K.S. | Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu) |
| EP3205646A3 (fr) | 2013-03-27 | 2017-10-04 | Laboratorios Lesvi, S.L. | Intermédiaires pour la fabrication de (r)-5-[2- (5,6-diéthylindan-2-ylamino)-1-hydroxyéthyl]-8-hydroxy-(1h)-quinolin-2-one (indacatérol) |
| EP3022201A1 (fr) | 2013-07-18 | 2016-05-25 | Novartis AG | Inhibiteurs de l'autotaxine |
| WO2015008230A1 (fr) | 2013-07-18 | 2015-01-22 | Novartis Ag | Inhibiteurs de l'autotaxine contenant un noyau à cycle benzyle-amide cyclique hétéroaromatique |
| WO2015104718A2 (fr) | 2014-01-09 | 2015-07-16 | Davuluri, Ramamohan Rao | Nouveau procédé de préparation d'indacatérol ou de ses sels pharmaceutiquement acceptables |
| RU2016141948A (ru) | 2014-03-27 | 2018-04-27 | Новартис Аг | Высушенные распылением дисперсии твердое-в-масле-в-воде активных фармацевтических ингредиентов для ингаляции |
| US20170037030A1 (en) | 2014-04-24 | 2017-02-09 | Novartis Ag | Autotaxin inhibitors |
| CN105693603B (zh) * | 2014-11-24 | 2019-11-29 | 上海医药工业研究院 | 改良的马来酸茚达特罗制备工艺 |
| KR101769204B1 (ko) * | 2015-08-04 | 2017-08-17 | 씨제이헬스케어 주식회사 | 크로마놀 유도체의 신규한 제조방법 |
| EP3347345B1 (fr) | 2015-09-29 | 2019-07-31 | Inke, S.A. | Solvate mixte de (r)-5-[2-(5,6-diéthylindan-2-ylamino)-1-hydroxyéthyl]-8-hydroxy-1h-quinolin-2-one l-tartrate |
| CN107394260B (zh) * | 2016-05-17 | 2020-06-09 | 财团法人工业技术研究院 | 金属离子电池 |
| CN107868045A (zh) * | 2016-09-28 | 2018-04-03 | 四川海思科制药有限公司 | 一种茚达特罗中间体的制备方法 |
| CN113731406B (zh) * | 2021-10-12 | 2023-07-28 | 南京工业大学 | 一种提高钯碳活性加氢脱除保护基的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9405019D0 (en) * | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| GB9913083D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| TWI324150B (en) * | 2003-02-28 | 2010-05-01 | Novartis Ag | Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt |
| PE20100399A1 (es) * | 2003-04-02 | 2010-06-01 | Novartis Ag | Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas |
-
2004
- 2004-06-22 GB GBGB0413960.6A patent/GB0413960D0/en not_active Ceased
-
2005
- 2005-06-17 AR ARP050102511A patent/AR049553A1/es not_active Application Discontinuation
- 2005-06-20 MY MYPI20052795A patent/MY142051A/en unknown
- 2005-06-20 PE PE2005000704A patent/PE20060304A1/es active IP Right Grant
- 2005-06-21 DE DE602005018076T patent/DE602005018076D1/de active Active
- 2005-06-21 PT PT05770221T patent/PT1791820E/pt unknown
- 2005-06-21 DK DK05770221.9T patent/DK1791820T3/da active
- 2005-06-21 JP JP2007517180A patent/JP5064214B2/ja active Active
- 2005-06-21 RU RU2007102228/04A patent/RU2383534C2/ru active
- 2005-06-21 TW TW094120524A patent/TWI347317B/zh active
- 2005-06-21 CA CA2566388A patent/CA2566388C/fr active Active
- 2005-06-21 NZ NZ551276A patent/NZ551276A/en unknown
- 2005-06-21 AU AU2005254698A patent/AU2005254698B2/en active Active
- 2005-06-21 EP EP05770221A patent/EP1791820B1/fr active Active
- 2005-06-21 BR BRPI0512298-8A patent/BRPI0512298A/pt not_active Application Discontinuation
- 2005-06-21 US US11/569,140 patent/US20090054653A1/en not_active Abandoned
- 2005-06-21 AT AT05770221T patent/ATE450512T1/de active
- 2005-06-21 ES ES05770221T patent/ES2337273T3/es active Active
- 2005-06-21 PL PL05770221T patent/PL1791820T3/pl unknown
- 2005-06-21 WO PCT/EP2005/006686 patent/WO2005123684A2/fr active Application Filing
- 2005-06-21 MX MXPA06014695A patent/MXPA06014695A/es active IP Right Grant
- 2005-06-21 KR KR1020067026958A patent/KR101179302B1/ko active IP Right Grant
- 2005-06-21 SI SI200530921T patent/SI1791820T1/sl unknown
- 2005-06-21 CN CN2005800195899A patent/CN1968927B/zh active Active
-
2006
- 2006-11-07 ZA ZA200609257A patent/ZA200609257B/en unknown
- 2006-11-27 IL IL179600A patent/IL179600A/en active IP Right Grant
- 2006-12-08 TN TNP2006000408A patent/TNSN06408A1/en unknown
- 2006-12-20 EC EC2006007100A patent/ECSP067100A/es unknown
- 2006-12-28 MA MA29571A patent/MA28687B1/fr unknown
-
2007
- 2007-01-22 NO NO20070400A patent/NO339079B1/no unknown
- 2007-09-25 HK HK07110434.6A patent/HK1105121A1/xx unknown
-
2010
- 2010-02-18 HR HR20100087T patent/HRP20100087T1/hr unknown
- 2010-03-01 CY CY20101100199T patent/CY1109884T1/el unknown
-
2011
- 2011-09-14 AR ARP110103340A patent/AR082981A2/es unknown
-
2012
- 2012-05-01 US US13/461,204 patent/US20120220775A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA28687B1 (fr) | Composes organiques | |
| Patel et al. | Synthesis of coumarin-based 1, 3, 4-oxadiazol-2ylthio-N-phenyl/benzothiazolyl acetamides as antimicrobial and antituberculosis agents | |
| UY28211A1 (es) | Compuestos de hidroximetilo | |
| NO20082719L (no) | Aryl-isoksazol-4-yl-oksadiazolderivater | |
| WO2008114819A1 (fr) | Nouveau composé d'adénine | |
| MA30991B1 (fr) | Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 | |
| WO2005092858A3 (fr) | Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1 | |
| PE20121312A1 (es) | Metodo para preparar compuestos macrociclicos inhibidores de serina proteasas de hepatitis c | |
| MA30411B1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
| ATE361916T1 (de) | Pyrimidine verbindungen | |
| AR060331A1 (es) | Un proceso convergente para la sintesis de derivados de taxano | |
| MA27930A1 (fr) | Derives de nicotinamide utiles comme inhibiteurs de pde4 | |
| ATE540928T1 (de) | Isochinolinverbindungen und ihre medizinische verwendung | |
| DE60236719D1 (de) | Purinderivate als antagonisten an purinergen rezeptoren | |
| MA31832B1 (fr) | Dérivés de quinazolinedione, leur préparation et leurs applications thérapeutiques | |
| MA31170B1 (fr) | Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer | |
| PE20061078A1 (es) | Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4) | |
| PE20061080A1 (es) | Compuestos derivados de piridotienopirimidina como inhibidores de fosfodiesterasa 4 | |
| CA2775354C (fr) | Agents antipaludiques inhibiteurs de la dihydro-orotate deshydrogenase | |
| MA29563B1 (fr) | Composes organiques | |
| TNSN07400A1 (fr) | Derives d'aminoacides | |
| MA31015B1 (fr) | Procede de fabrication de 4.4'- (1-methyl-1,2-ethandiyl)-bis -(2,6-piperazindione) | |
| KR880013920A (ko) | 디하이드로피리딘 화합물 및 이의 제조방법 | |
| GB0412314D0 (en) | Compounds | |
| AR057823A1 (es) | Compuestos quimicos derivados de quinazolina, un metodo para su preparacion y composicion farmaceutica |